Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in pituitary stem cells | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 41 | 0.91 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 9569
Sealed predictions
- CNTN3 in oligodendrocytes, braak+0.21 (p 0.586) → -0.34 (p 0.378)receipt 9577
- CNTN3 in dopamine neurons, braak+0.82 (p 0.007) → +0.62 (p 0.076)receipt 9578
Swarm cases
receipt 9578: CNTN3 in dopamine neurons, braak
- power
- full sample +0.65 (p 0.0037, n 18), 95% CI +0.26 to +0.86. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.65 (p 0.0037, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.64 (p 0.0045, n 18). not the mix.
- skeptic
- leave-one-out range +0.59 to +0.75, sign flips 0; without severely affected donors +0.65 (p 0.0037, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CNTN3 in dopamine neurons.
case closed: nothing better to follow up.
receipt 9577: CNTN3 in oligodendrocytes, braak
- power
- full sample -0.04 (p 0.867, n 18), 95% CI -0.50 to +0.43. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.14 (p 0.579, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.07 (p 0.781, n 18). could be the mix.
- skeptic
- leave-one-out range -0.14 to +0.09, sign flips 4; without severely affected donors -0.04 (p 0.867, n 18). fragile.
- cell type
- strongest in dopamine neurons: +0.65 (p 0.0037, n 18) vs -0.04 in oligodendrocytes. proposing dopamine neurons.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CNTN3 in oligodendrocytes.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CNTN3 · dopamine neurons · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.23 p 0.424 (needs p < 2.2e-4)
Receipts
loading the receipts